RxDoctor Payments Data

Mark Sczepanski, MD

Ophthalmology · Grand Forks, NDNPI 1295731040

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $168 of the $225 with a category attached, or 74.6%. Alcon accounts for 72.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $164 and has fallen 90.2% since, to $16 in 2023. That places this record below the midpoint for ophthalmology clinicians in ND, where the typical reported total is $449.

$225in general payments, 2019–2025

Across 5 payments — averaging $45.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$164
  • AbbVie$45
  • Glaukos Corporation$16

What the payments were for

  • Travel & lodging$125%
  • Food & beverage$16875%
  • Gifts$4520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon3$164
AbbVie1$45
Glaukos Corporation1$16

How this compares

$225 in reported general payments places this provider in the 35th percentile of 41 ophthalmology providers in North Dakota.

See all ophthalmology providers in North Dakota

Medicare billing

Part B allowed, 2024
$794,446
Medicare patients
1,171
Services billed
4,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost104$31,892
Prednisolone Acetate378$23,171
RocklatanNetarsudil Mesylat/Latanoprost49$18,365
RhopressaNetarsudil Mesylate22$9,942
CombiganBrimonidine Tartrate/Timolol30$7,361
AzoptBrinzolamide16$6,191
Ketorolac Tromethamine388$5,855
Latanoprost404$5,759
Ofloxacin358$5,446
Brinzolamide13$4,058
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat189$3,918
Brimonidine Tartrate91$3,659
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$3,239
Timolol Maleate111$2,040
Travoprost11$1,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$45$39,253134 claims
AlconAzopt$164$6,19116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 41 ophthalmology providers in North Dakota.

Other ophthalmology in Grand Forks

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →